CMS Open Payments · Program Year 2024
Biofrontera Inc.
Biofrontera Inc. reported $633,335.94 across General Payments, Research, and Ownership to 5,338 physicians and teaching hospitals across 5,370 transactions.
- $633.3K
- All-tracks total
- 5,370
- Transactions
- 5,338
- Recipients
- +$40.9K
- General Payments vs PY2023
Biofrontera Inc. reported $633,335.94 across all CMS Open Payments tracks (General + Research + Ownership) to 5,338 physicians and teaching hospitals in Program Year 2024 - ranking #715 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $252,582.78, averaging $118.65 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biofrontera-inc Biofrontera Inc.
$633.3K · #715/1,925 · 0.0% industry · PY2024
- TOT $633.3K
- RANK #715
- SHARE 0.0%
- TXN 5,370
- RCP 5,338
- CAT 7
- GEN $252.6K
- ΔGEN +$40.9K
- TOP1 8.5%
- PY 2024
Volume peers
Nearest volume peer: Roche Diagnostics International Ltd ($627.8K)
Biofrontera Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Biofrontera Inc.'s CMS-reported General Payments increased by $40.9K (+19.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BIOFRONTERA INC.PY2023: BIOFRONTERA INC.PY2024: Biofrontera Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $211,726.88
- PY2024
- $252,582.78
What the Data Shows for Biofrontera Inc.
$633,335.94: that is what Biofrontera Inc. reported in payments to 5,338 physicians and teaching hospitals during Program Year 2024, spread across 5,370 transactions ($117.94 per transaction, $118.65 per recipient). The company sits at rank #715 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
The 7-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $101.8K, accounting for 40.3% of this company's General Payments and 5,271 transactions.
General Payment Breakdown by Type
"Food and Beverage" leads Biofrontera Inc.'s 7-category general-payment breakdown at $101.8K, 40.3% of the reported total.
Biofrontera Inc. reports 7 general-payment categories - the top three are Food and Beverage (40.3%), Consulting Fee (32.8%), and Debt Forgiveness (23.5%). The remaining 4 categories make up 3.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Biofrontera Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $101.8K | 5,271 | 40.3% |
| Consulting Fee | $82.9K | 58 | 32.8% |
| Debt Forgiveness | $59.3K | 5 | 23.5% |
| Compensation for Services Other Than Consulting | $2.5K | 1 | 1.0% |
| Grant | $2.5K | 1 | 1.0% |
| Compensation for Faculty or Speaker (Medical Education) | $2.0K | 1 | 0.8% |
| Honoraria | $1.5K | 1 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $68,090.96 (27.0%) of $252,582.78 in this company's General Payments records across 3,216 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Biofrontera Inc.
The five named recipients with the highest reported General Payments from this company
- 1
David Stockman
$21,456.19 across 1 reported transactions
- 2
Ravindrakumar Gangadhariah
$15,792.00 across 1 reported transactions
- 3
Peter Jenkin
$12,897.20 across 1 reported transactions
- 4
David Goldberg
$10,500.00 across 2 reported transactions
- 5
Mark Kaufmann
$7,445.57 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Biofrontera Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Biofrontera Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Biofrontera Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Inquis Medical, Inc.
Edap Technomed Inc
Canon Medical Systems USA, Inc.
Volta Medical Inc
Carlsmed, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.